Chidamide
| Title | Journal |
|---|---|
| Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells. | Biochemical and biophysical research communications 20130426 |
| Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. | PloS one 20130101 |
| Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. | Cancer chemotherapy and pharmacology 20120601 |
| Antitumor activity of Chidamide in hepatocellular carcinoma cell lines. | Molecular medicine reports 20120601 |
| CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. | The Biochemical journal 20120501 |
| Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. | Cancer chemotherapy and pharmacology 20120401 |
| Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy. | Bioorganic & medicinal chemistry letters 20110101 |
| A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. | Biochemical and biophysical research communications 20100205 |